|  |  |  |  |
| --- | --- | --- | --- |
| **Criteria Title** | Central Nervous System Agents | | |
| **Criteria Subtitle** | Nuedexta (dextromethorphan hydrobromide / quinidine sulfate) | | |
| **Approval Level** | GCNSeqNo | | |
| **Products**   |  |  | | --- | --- | | Preferred |  | | Non-Preferred |  | | Brand |  | | Generic |  | | Other |  | | Drug Name | Corresponding Code(s) | Type of Code (GCNSeqNo, HICL, NDC) |
| NUEDEXTA | 066871 | GCNSeqNo |

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **Sequence Number** | **Question ID** | **Default Next Question ID** | **Question Type** | **Question Text** | **Choice Text** | **Next Question ID** |
| 1 | 0998 |  | Select | Is the patient new to therapy (initial authorization request) or continuing therapy (re-authorization request)? | New Start (initial authorization request) | 0999 |
| Continuation (re-authorization request) | 2000 |
| 2 | 0999 |  | Select | Is this request being prescribed in accordance with Food and Drug Administration (FDA) approved labeling? | Y | 1000 |
| N | 1235 |
| 3 | 1000 |  | Select and Free Text | Has the patient had an inadequate clinical response to a tricyclic  antidepressant (TCA) or a selective serotonin reuptake inhibitor (SSRI)?  If yes, please submit the medication trials and dates. | Y | 1002 |
| N | 1001 |
| 4 | 1001 |  | Select and Free Text | Does the patient have a contraindication to a tricyclic  antidepressant (TCA) or a selective serotonin reuptake inhibitor (SSRI)?  If yes, please submit the medication name and reason for inability to use. | Y | 1002 |
| N | 1235 |
| 5 | 1002 |  | Select  and Free Text | Has the provider submitted documentation that patient’s baseline Center for Neurologic Study-Lability Scale (CNS-LS) score is greater than 13?    If yes, please provide documentation. | Y | END (Pending Manual Review) |
| N | 1235 |
| 6 | 2000 |  | Select and Free Text | Has the provider submitted documentation of a positive response to therapy as  evidenced by a decrease in the Center for Neurologic Study-Lability Scale (CNS-LS) score of at least 3 points from baseline?    If yes, please provide documentation. | Y | END (Pending Manual Review) |
| N | 1235 |
| 7 | 1235 |  | Free Text | Please provide the rationale for the medication being requested. | END (Pending Manual Review) | |

LENGTH OF AUTHORIZATIONS: Initial authorizations will be for 84 days; subsequent authorizations will be for 365 days.

|  |  |
| --- | --- |
| **Last Approved** | 4/13/2023 |
| **Other** |  |